New England Research & Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-14,955
| Closed | -$807K | – | 147 |
|
|
2025
Q4 | $807K | Sell |
14,955
-11,706
| -44% | -$563K | 0.35% | 80 |
|
|
2025
Q3 | $1.2M | Sell |
26,661
-2,908
| -10% | -$136K | 0.55% | 63 |
|
|
2025
Q2 | $1.37M | Sell |
29,569
-700
| -2% | -$34.4K | 0.65% | 50 |
|
|
2025
Q1 | $1.85M | Buy |
30,269
+4,180
| +16% | +$244K | 0.94% | 30 |
|
|
2024
Q4 | $1.48M | Sell |
26,089
-27,749
| -52% | -$1.55M | 0.75% | 43 |
|
|
2024
Q3 | $2.79M | Sell |
53,838
-100
| -0.2% | -$4.69K | 1.31% | 16 |
|
|
2024
Q2 | $2.24M | Buy |
53,938
+3,931
| +8% | +$176K | 1.08% | 24 |
|
|
2024
Q1 | $2.71M | Buy |
50,007
+4,655
| +10% | +$237K | 1.33% | 16 |
|
|
2023
Q4 | $2.33M | Sell |
45,352
-2,045
| -4% | -$107K | 1.23% | 21 |
|
|
2023
Q3 | $2.75M | Sell |
47,397
-755
| -2% | -$46.3K | 1.57% | 11 |
|
|
2023
Q2 | $3.08M | Buy |
48,152
+5,405
| +13% | +$362K | 1.79% | 14 |
|
|
2023
Q1 | $2.96M | Buy |
42,747
+4,400
| +11% | +$310K | 1.74% | 13 |
|
|
2022
Q4 | $2.76M | Buy |
38,347
+3,000
| +8% | +$226K | 1.59% | 15 |
|
|
2022
Q3 | $2.51M | Buy |
35,347
+10,715
| +44% | +$777K | 1.58% | 16 |
|
|
2022
Q2 | $1.9M | Sell |
24,632
-10,012
| -29% | -$763K | 1.1% | 28 |
|
|
2022
Q1 | $2.53M | Sell |
34,644
-793
| -2% | -$53.2K | 1.31% | 20 |
|
|
2021
Q4 | $2.21M | Sell |
35,437
-2,300
| -6% | -$135K | 1.07% | 23 |
|
|
2021
Q3 | $2.23M | Buy |
37,737
+4,550
| +14% | +$300K | 1.17% | 22 |
|
|
2021
Q2 | $2.22M | Sell |
33,187
-350
| -1% | -$22.8K | 1.15% | 19 |
|
|
2021
Q1 | $2.12M | Buy |
33,537
+10,850
| +48% | +$675K | 1.16% | 23 |
|
|
2020
Q4 | $1.41M | Sell |
22,687
-12,075
| -35% | -$742K | 0.87% | 35 |
|
|
2020
Q3 | $2.1M | Sell |
34,762
-4,375
| -11% | -$263K | 1.52% | 16 |
|
|
2020
Q2 | $2.3M | Buy |
39,137
+3,800
| +11% | +$227K | 1.65% | 13 |
|
|
2020
Q1 | $1.97M | Buy |
35,337
+4,300
| +14% | +$263K | 1.68% | 16 |
|
|
2019
Q4 | $1.99M | Sell |
31,037
-1,650
| -5% | -$94.5K | 1.33% | 17 |
|
|
2019
Q3 | $1.66M | Sell |
32,687
-350
| -1% | -$16.4K | 1.2% | 20 |
|
|
2019
Q2 | $1.5M | Sell |
33,037
-700
| -2% | -$32.6K | 1.02% | 23 |
|
|
2019
Q1 | $1.61M | Buy |
33,737
+10,320
| +44% | +$514K | 1.09% | 26 |
|
|
2018
Q4 | $1.22M | Buy |
23,417
+7,650
| +49% | +$411K | 0.96% | 28 |
|
|
2018
Q3 | $979K | Sell |
15,767
-50
| -0.3% | -$2.97K | 0.64% | 60 |
|
|
2018
Q2 | $875K | Sell |
15,817
-750
| -5% | -$40.5K | 0.58% | 63 |
|
|
2018
Q1 | $1.05M | Sell |
16,567
-6,100
| -27% | -$392K | 0.7% | 59 |
|
|
2017
Q4 | $1.39M | Sell |
22,667
-1,950
| -8% | -$122K | 0.99% | 33 |
|
|
2017
Q3 | $1.57M | Sell |
24,617
-4,275
| -15% | -$250K | 1.15% | 23 |
|
|
2017
Q2 | $1.61M | Buy |
28,892
+575
| +2% | +$31.3K | 1.19% | 18 |
|
|
2017
Q1 | $1.54M | Buy |
28,317
+2,300
| +9% | +$126K | 1.18% | 19 |
|
|
2016
Q4 | $1.52M | Buy |
26,017
+5,150
| +25% | +$282K | 1.19% | 17 |
|
|
2016
Q3 | $1.13M | Buy |
20,867
+13,717
| +192% | +$881K | 0.94% | 31 |
|
|
2016
Q2 | $526K | Sell |
7,150
-9,400
| -57% | -$664K | 0.45% | 73 |
|
|
2016
Q1 | $1.06M | Buy |
16,550
+600
| +4% | +$37.8K | 0.9% | 35 |
|
|
2015
Q4 | $1.1M | Buy |
15,950
+200
| +1% | +$13.2K | 0.95% | 27 |
|
|
2015
Q3 | $932K | Buy |
15,750
+5,350
| +51% | +$339K | 0.89% | 32 |
|
|
2015
Q2 | $692K | Sell |
10,400
-250
| -2% | -$16.5K | 0.57% | 66 |
|
|
2015
Q1 | $687K | Sell |
10,650
-700
| -6% | -$43.8K | 0.59% | 68 |
|
|
2014
Q4 | $670K | Buy |
11,350
+750
| +7% | +$42.3K | 0.57% | 70 |
|
|
2014
Q3 | $543K | Sell |
10,600
-1,600
| -13% | -$79.9K | 0.47% | 91 |
|
|
2014
Q2 | $592K | Buy |
+12,200
| New | +$601K | 0.53% | 82 |
|
Other funds holding BMY
VCM
VPM
New England Research & Management's BMY Position: Q1 2026 in Review
New England Research & Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 14,955 shares — an estimated $807K sold.
New England Research & Management first reported a position in BMY in Q2 2014 and held it in 47 quarters. The position peaked at $3.08M in Q2 2023. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- New England Research & Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- New England Research & Management sold 14,955 Bristol-Myers Squibb shares in Q1 2026, an estimated $807K.
- New England Research & Management first reported a position in Bristol-Myers Squibb in Q2 2014 and held it in 47 quarters.
- New England Research & Management's Bristol-Myers Squibb position peaked at $3.08M in Q2 2023.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on New England Research & Management's 13F filing for Q1 2026, filed 7 May 2026.